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Introduction 
This report is based on data provided by countries for reporting on the Dublin Declaration [1] and summarises key 
issues related to HIV and people who inject drugs (PWID) in Europe and Central Asia. It also identifies priority 
options for action to improve the HIV response for this population. 
Methodology 
Between January and March 2018, a survey was carried out by the European Centre for Disease Prevention and 
Control (ECDC) to collect data to monitor implementation of the 2004 Dublin Declaration [1]. The monitoring 
questionnaire was disseminated to the 53 countries that are part of the WHO European Region, plus Kosovo1 and 
Liechtenstein via an online survey. National health authorities were requested to complete the Dublin Declaration 
survey between mid-February and the end of March 2018. 
ECDC further harmonised data collection with UNAIDS and WHO’s Regional Office for Europe to ensure 
compatibility and reduce burden on health authorities. ECDC took responsibility for collecting a core set of Global 
AIDS Monitoring (GAM) indicators through Dublin Declaration implementation monitoring for EU/EEA Member 
States, meaning there was no separate GAM reporting for EU/EEA Member States. Non-EU/EEA Member States 
continued to report to GAM through UNAIDS and were therefore asked to complete a shortened ECDC Dublin 
Declaration questionnaire, with any GAM questions removed. The data collected through these processes were 
then combined and included in the analysis for this report.  
In May 2018, the information reported by each country was cleaned up and returned for validation. Subsequent 
notifications of corrections were used to update the information reported. Validation of data collected through the 
GAM process was conducted by UNAIDS. 
The survey contained specific questions in relation to the HIV epidemic among people who inject drugs (PWID) in 
addition to questions relating to current national prevention interventions, policies and barriers to the public health 
response to the epidemic. 
This report presents the situation among people who inject drugs (PWID), a key group affected by HIV in the WHO 
European Region. As well as considering the picture for the overall European and Central Asian region, findings are 
presented by WHO sub-regions (West, Centre, and East). This is the approach used in the joint ECDC/WHO report 
on HIV/AIDS surveillance in Europe [2], which broadly group areas of Europe and Central Asia by geography and 
epidemic type, as depicted in Figure 1. In addition, case studies provided by health authorities highlight 
developments in public health policy and programme implementation, specific to PWID. 
The report presents disaggregated data, where available, for PWID for the continuum of HIV care across the region 
and classifies results according to countries that reported: (a) all four stages2, (b) no stages, and (c) at least two 
consecutive stages of the continuum of care. Findings are compared against the global 90:90:90 targets [3].  
Unless otherwise indicated, the data source for all graphs presented is the Dublin Declaration monitoring process 
for 2018. 
Data from the ECDC survey have been supplemented by data from the European Surveillance System (TESSy) for 
the WHO European Region and from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 
relation to EU countries plus Norway and Turkey. 
  
 
                                                                    
1 This designation is without prejudice to positions on status and is in line with UNSC 1244 and the ICJ Opinion on the Kosovo 
Declaration of Independence. 
2 For the four stages of the continuum of care see Table 1 below. 
Countries covered by the report are grouped as follows: 
West, 24 countries: Andorra, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, 
Israel, Italy, Luxembourg, Liechtenstein, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, 
Sweden, Switzerland, United Kingdom 
Centre, 16 countries: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, 
Kosovo, North Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey.  
East, 15 countries: Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, 
Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan 
HIV and people who inject drugs TECHNICAL REPORT 
2 
Figure 1. Geographical/epidemiological division of the WHO European Region  
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Why focus on people who inject drugs? 
HIV disproportionally affects people who inject drugs (PWID) on a global basis. HIV and other blood borne viruses can 
be transmitted through the sharing of injecting equipment including needles, syringes and other paraphernalia. 
Injecting drug use is a significant mode of HIV transmission in the European Region (Figure 2). In 2017, 13% of all 
new HIV diagnoses in the European Region were among PWID. The majority of people diagnosed with HIV who had a 
history of injecting drugs were from the East sub-region, and 24% of the new diagnoses in this sub-region in 2017 
were attributed to injecting drug use (compared with 2.7 % in both West and Centre sub-regions). As seen in Figure 
2, Kazakhstan, Kyrgyzstan, Iceland, Latvia, Lithuania and Ukraine all reported that over 25% of people newly 
diagnosed with HIV in 2017 had a history of injecting drugs. There are also significant epidemics in Armenia, Belarus, 
Georgia, Greece and Tajikistan. While information on transmission mode from Russia is not available, the overall 
number of new diagnoses in Russia accounted for 65% of all new HIV diagnoses in the European Region in 2017 [2], 
and injecting drug use is known to be the main route of transmission in that country [4]. 
Figure 2. Proportion of new HIV diagnoses acquired through injecting drug use in 2017 
 
Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2018–2017 data. 
Over the past ten years, the number of people diagnosed with HIV who inject drugs declined by 38% (from 11 034 
in 2008 to 6 893 in 2017), largely due to decreases in the East sub-region (a fall of 36% from 10 006 to 6 361) 
and this decline was particularly apparent in the Ukraine and Azerbaijan. Despite this, the East sub-region 
continues to account for about 92% of all PWID newly diagnosed with HIV in the European Region, a similar 
proportion to a decade ago. Furthermore, the absence of Russian data means the extent of the current PWID 
epidemic in the East sub-region is substantially under-documented. 
Figure 3. New HIV diagnoses among people who inject drugs (PWID) by year of diagnosis and WHO sub-
region, 2008–2017 
Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2018 – 2017 data 
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Prevalence data on HIV among PWID from national and sub-national studies are available from 41 of the 55 
countries in the Region (see Figure 4)3. Of the 14 countries which did not provide data, six are in the EU/EEA. 
Prevalence ranged across the region from 0% reported by North Macedonia, Slovenia and Turkey, to 54% in 
Estonia. Three countries have a prevalence rate of between 6 and 10% (Azerbaijan, Kazakhstan and Switzerland); 
seven countries have a prevalence rate of between 11 and 20% (Belgium, Kyrgyzstan, Luxembourg, Moldova, 
Portugal, Romania and Tajikistan) and seven countries have a prevalence of over 20% (Belarus, Estonia, Italy, 
Latvia, Russia, Spain and Ukraine).  
It should be noted that the accepted definition of a concentrated epidemic is more than 5% HIV prevalence in a 
key population. On that basis, nineteen countries across the European Region have a concentrated epidemic 
among PWID - eleven are in the East sub-region, seven in the West and one in the Centre sub-region. Nine of the 
19 countries with prevalence above 5% are EU/EEA countries. 
It remains vital to implement a full range of prevention and harm reduction measures, as well effective surveillance 
for this key population. This is the case even for lower prevalence countries since HIV can spread rapidly among 
PWID. Recent reported outbreaks have occurred in Luxembourg in 2014 [5], Ireland (specifically Dublin) in 2015 
[6], the United Kingdom (specifically Glasgow) in 2015 [7], Germany (specifically Bavaria) in 2017 [8], and 
Lithuania in 2018 [8]. All of these are countries with an estimated HIV prevalence among PWID of <5%. 
Figure 4. Available data on HIV prevalence among PWID across Europe and Central Asia, 2011–2017 
 
  
 
                                                                    
3 Whilst the majority of the prevalence data reported were published between 2015 and 2017, data from some countries are not 
recent - Switzerland’s data is from 2011; Serbia and Germany’s from 2013; and Montenegro, Finland, and Tajikistan’s from 2014. 
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Progress and remaining challenges 
Continuum of HIV care 
The continuum of HIV care is a conceptual framework that provides a snapshot of critical stages in achieving viral 
suppression among people living with HIV (PLHIV) [9]. It has become one of the central metrics through which the 
public health response to HIV is evaluated at the local, national and international level [10]. In 2014, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) established the 90-90-90 targets for three of the four stages of 
the continuum of HIV care, the aim being that by 2020, 90% of all people living with HIV are diagnosed, 90% of 
those diagnosed receive treatment and 90% of those receiving treatment achieve viral suppression. This translates 
to a target of 73% viral suppression among all PLHIV. To be able to report on each of the three ‘90’ targets it is 
necessary to have data for the two relevant consecutive stages of the continuum of care. The definitions for each 
of the four stages of the continuum of care are provided in Table 1. 
Table 1. Consensus definitions for monitoring the continuum of HIV care during Dublin Declaration 
monitoring 2018  
Stage 1: Total estimated number of people living with HIV in the country 
The total estimated number should be based on an empirical modelling approach, using the ECDC HIV 
Modelling Tool4, Spectrum or any other empirical estimate. The estimate should include diagnosed 
and undiagnosed people. 
Stage 2: Number/percentage of above (estimated number of people living with HIV in the 
country) ever having been diagnosed 
The number should include all new HIV or AIDS diagnoses. It should also include those people who 
are in care and those who have not been linked to care. 
Stage 3: Number/percentage of above (estimated number of people living with HIV in the 
country, ever having been diagnosed) who are currently on antiretroviral treatment 
The number should include all people currently on ART, regardless of treatment regimen or treatment 
interruptions/discontinuation. 
Stage 4: Number/percentage of above (estimated number of people living with HIV in the 
country, ever having been diagnosed or having initiated antiretroviral treatment) who 
had viral load (VL) ≤200 copies/ml at last visit (virally suppressed)5 
The number should include all those who have ever initiated ART, regardless of regimen or treatment 
interruptions/discontinuation. 
Breaking down the continuum of care by key population allows countries to measure outcomes for groups who are 
disproportionately affected by HIV. It also means that disparities between key populations that are hidden at the 
aggregate level can be better understood. 
Data for the continuum of care among PWID living with HIV in Europe and Central Asia are limited. In 2018, data 
about all four stages were reported by seven countries for PWID, one fewer than in 2016 (Figure 5). However, 
there was some slight improvement in data coverage overall between 2016 and 2018. Between 2016 and 2018, 
there was an increase in the number of countries reporting data for stages 2, 3 and 4 of the continuum of care for 
PWID. At least two consecutive stages were reported by 16 countries. There was also a reduction in the number of 
countries who were unable to report data for any stages of the continuum of care for PWID. 
  
 
                                                                    
4 ECDC Modelling Tool. http://ecdc.europa.eu/en/healthtopics/aids/Pages/hiv-modelling-tool.aspx  
5 A viral load threshold for viral suppression of <200 copies/mL was used to allow for changes over time in the lower detection 
limits of viral load assays. A threshold of 200 copies/mL for population-level monitoring is consistent with recommendations in a 
recent systematic review of guidelines produced by IAPAC - www.iapac.org/uploads/JIAPAC-IAPAC-Guidelines-for-Optimizing-the-
HIV-Care-Continuum-Supplement-Nov-Dec-2015.pdf and the US Centers for Disease Control and Prevention - 
www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf  
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Figure 5. Number of countries reporting data for different stages of the HIV continuum of care for 
people who inject drugs, Europe and Central Asia, reported in 2016 and 2018 
 
Figure 6 provides more detail for those countries which reported data for PWID across two consecutive stages of 
the continuum of care and so can report values against the UNAIDS 90-90-90 targets.  
Eight countries provided data on the percentage of PWID living with HIV who are aware of their status – the first 
90 target. The percentage of estimated PWID living with diagnosed HIV ranged from 75% to 98% (see Figure 6a). 
This figure is affected not just by testing rates but by incidence and migration, as well as by the accuracy of 
information on the estimated size of the denominator – stage 1 (i.e. the total number of PWID who are living with 
HIV). It is worth noting that all eight countries (Figure 6a) who could provide information on the percentage of 
PWID living with HIV who know their status also had data on the percentage of PWID who had tested in the last 
12 months. Moreover, seven of these eight countries had a value of around 50% or significantly higher. The one 
exception was Azerbaijan which reported 80% of people who inject drugs and living with HIV knowing their status, 
but only 12.2% of people who inject drugs having tested for HIV in the previous 12 months. 
Fourteen countries were able to report the percentage of PWID living with diagnosed HIV who are on treatment in 
2018 (Figure 6b) – the second 90 target. Six of the 14 exceeded the UN target of 90% – Malta, Switzerland, 
Sweden, Austria, France and the United Kingdom. Meanwhile Luxembourg, at 88%, is not far short of the target. 
However, other countries have some way to go: Georgia, Greece and Belgium had percentages in the 70s, and 
Kazakhstan and Azerbaijan in the 40s. In the latter two countries, there is clearly important work to be done to 
improve linkage to and retention in care. However, at least all of the 14 countries have data from which they can 
identify priorities for their HIV response. It is alarming to see the large number of countries (41/55) which did not 
report any data for this target.  
The same data gap is evident for the percentage of those PWID on treatment who have reached viral suppression 
(the third 90 target), where again only 12 countries were able to report any data (Figure 6c). Seven countries had 
met the UN target of 90% - Switzerland, France, United Kingdom, Luxembourg, Germany, Belgium and Sweden. 
Both Austria and Georgia, at 82%, are making good progress towards the 90% target. However, Azerbaijan (55%), 
Kazakhstan (53%) and Bulgaria (31%) still have a considerable way to go to reach the UN target and detailed work 
is needed to understand the reason for these lower percentages. 
The ECDC report ‘Continuum of HIV Care. Monitoring implementation of the Dublin Declaration on partnership to fight 
HIV/AIDS in Europe and Central Asia: 2018 Progress Report’ has previously discussed the need to improve data 
across the continuum of care for PWID. Only six countries (France, Luxembourg, Austria, United Kingdom, 
Kazakhstan and Azerbaijan) could report data for all four stages to provide an estimate of the percentage of all 
PWID living with HIV who are virally suppressed against the UN target of 73% (and only one country, France, has 
met and exceeded this target for PWID – see Figure 6d).  
The graphs in Figure 6 also compare outcomes for PWID with those reported by the relevant countries for all 
people living with HIV (PLHIV). Overall, there are few substantial variations in outcome between PWID and PLHIV 
in general, apart from diagnosis and viral suppression in the UK; the percentage of those diagnosed on treatment 
in Belgium, Azerbaijan and Belarus and the percentage of those on treatment who are virally suppressed for 
Bulgaria. Again, it is unwise to draw general conclusions for the Region from a relatively small number of reporting 
countries. However, this does demonstrate that it is perfectly possible for outcomes relating to PWID to be as good 
as those for PLHIV, if resources and targeted services are put in place to address the specific needs of this key 
population. 
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Figure 6. Estimates provided for each stage of the continuum of care for PWID living with HIV in Europe and 
Central Asia compared to national outcomes, reported in 20186 
 
 
 
Combination prevention 
HIV combination prevention is an approach that brings together single prevention initiatives into a comprehensive 
programme [11]. Importantly, the specific elements take effect across the life course of HIV infection and 
encompass primary prevention (preventing people without the virus from acquiring HIV infection), secondary 
prevention (preventing onward transmission from those living with HIV) and structural tertiary intervention (to 
improve health-related quality of life of those living with HIV). The interventions implemented will vary depending 
on the needs of the key population, but it is important that they are implemented at scale and in combination to 
maximise their benefits. 
ECDC and EMCDDA have published guidance (2011) on the prevention and control of infectious diseases among 
people who inject drugs. The guidance recommends seven key intervention components to address infectious 
disease, including HIV, among PWID [12]. These are listed in Table 2. 
  
 
                                                                    
6 Austria, Belarus and Israel are excluded from Figure 6a, and Belarus is also excluded from Figure 6c and 6d, due to anomalous 
results. The number of countries reporting in Figure 6b is larger than the number in Figure 5 reporting data on treatment 
numbers because two countries, Switzerland and Germany, reported percentages based on cohort data and chose not to provide 
absolute numbers. 
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Table 2. Key intervention components 
Key intervention components 
Injection equipment: provision of, and legal access to, clean drug injection equipment, including sufficient 
supply of sterile needles and syringes free of charge, as part of a combined multi-component approach, 
implemented through harm-reduction, counselling and treatment programmes. 
Vaccination: hepatitis A and B, tetanus, influenza vaccines, and for HIV-positive individuals in particular, 
pneumococcal vaccine. 
Drug dependence treatment: opioid substitution treatment and other effective forms of drug-dependence 
treatment. 
Testing: voluntary and confidential testing with informed consent for HIV, HCV (HBV for unvaccinated) and 
other infections, including TB, should be routinely offered and linked to treatment referral. 
Infectious disease treatment: antiviral treatment based on clinical indications for those with HIV, HBV or 
HCV infection. Anti-tuberculosis treatment for active TB cases. TB prophylactic therapy should be considered for 
latent TB cases. Treatment for other infectious diseases should be offered as clinically indicated.  
Health promotion: health promotion focused on safer injecting behaviour; sexual health, including condom 
use; and disease prevention, testing and treatment. 
Targeted delivery of services: services should be combined, organised and delivered according to user 
needs and local conditions. This includes the provision of services through outreach and fixed site settings 
offering drug treatment, harm reduction, counselling and testing, as well as referrals to general primary health 
and specialist medical services.  
Evidence also indicates that health facilities where drug use is supervised by professional staff and takes place in a 
clean and safe environment (so-called Drug Consumption Rooms, DCRs) are beneficial for reaching marginalised 
groups. For those who use them regularly, such facilities are also effective in reducing harm related to injecting 
drug use, including risk behaviour that enables the transmission of infectious diseases [13]. DCRs have mainly 
been set up in cities with high levels of concentrated drug use in public spaces, where they form an important part 
of a comprehensive response in order to reduce health harm and improve public safety.  
Countries were asked whether they implemented a range of specified interventions to prevent the transmission of 
infections among PWID. Responses are shown in Figure 7, where the interventions have been categorised into 
those with a primary focus on ‘preventing HIV acquisition’; those with a secondary prevention element of 
‘preventing onward HIV transmission’; and those with a broader focus of ‘improving health-related quality of life’. 
Of course many of the interventions which prevent HIV acquisition also contribute towards preventing onward 
transmission (e.g. condoms and needle and syringe provision), and some also contribute to improving health-
related quality of life (e.g. Opioid Substitution Therapy (OST) and Drug Consumption Rooms (DCR) reduce the 
potential for overdosing and improve engagement with care).  
While a significant majority of countries do have a policy to implement key interventions, such as Needle and 
Syringe Programmes (NSPs) and OST, there is a substantial drop-off in implementation of prevention interventions 
in prisons for PWID, lower rates of healthcare interventions such as vaccination programmes, and more to do in 
relation to testing and the sexual health of PWID. A detailed country breakdown can be seen in Annex 1. A more 
detailed report on combination prevention based on the responses to the 2018 Dublin Declaration reporting 
process will also be published at a later date. 
  
TECHNICAL REPORT  HIV and people who inject drugs  
9 
Figure 7. Number of European and Central Asian countries implementing selected interventions, 2018 
 
Preventing HIV acquisition 
Needle and Syringe Programmes (NSPs) 
Forty-four of the 52 responding7 countries reported that they implemented needle and syringe programmes (NSPs) 
for PWID. Whilst this suggests a widespread acceptance of this harm reduction measure, it does not offer a 
realistic picture of coverage and provision. The international standard of acceptable coverage for PWID is at least 
200 needles distributed per person per year8 [14]. Eleven countries provided no data on the number of syringes 
distributed per person who injects drugs. Only eight countries in the Region reported meeting this international 
standard for needle distribution (≥200) – Austria, Croatia, Estonia, Finland, Kyrgyzstan, Luxembourg, Norway and 
Tajikistan (see Figure 8). A further eleven countries reported distribution of between 100 and 200 needles per 
person per year (Bosnia & Herzegovina, Czech Republic, France, Ireland, Kazakhstan, Malta, Montenegro, Portugal, 
Slovenia, Spain and Uzbekistan). Only six countries with an HIV prevalence of 11% or over among people who 
inject drugs also report a distribution of at least 100 needles per person per year, and of those only two are non-
EU/EEA countries (Kyrgyzstan and Tajikistan).  
  
 
                                                                    
7 Andorra and Turkey reported that NSPs are not implemented. Iceland responded, ‘Don’t know’. Five countries – Liechtenstein, 
Monaco, Russia, Tajikistan and Uzbekistan – did not respond to the question. The three countries which did not respond to the 
2018 Dublin Declaration reporting process were Bosnia & Herzegovina, San Marino and Turkmenistan. 
8 The WHO target to reach by 2020 is 200 sterile needles and syringes provided per person who injects per year, and the target 
to reach by 2030 is 300. 
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Figure 8. Available data on number of syringes distributed per person per year, 2018 
 
Source: EMCDDA Statistical Bulletin 2018 and ECDC Dublin Declaration monitoring 2018. 
Increasing accessibility to harm reduction  
The national health authority in Latvia reports that since January 2017 a new harm reduction mobile unit has 
been operating in the capital, Riga, and its surrounding neighbourhoods. The mobile unit operates 23 hours per 
week over four days. It has several employees, including medical, social and outreach workers. The mobile unit 
provides syringes and needles, condoms, specialist consultations, informative materials for clients, and rapid 
testing for HIV, hepatitis B and C and syphilis. 
Drug Consumption Rooms 
Only a few countries report provision of Drug Consumption Rooms (DCRs), despite their documented effectiveness 
in reducing injecting risk behaviour and overdose morbidity and mortality and in creating opportunities for users to 
access wider care and support services [13]. In 2018, Belgium, Denmark, France, Germany, Luxembourg, 
Netherlands, Norway, Spain and Switzerland reported the availability of DCRs (see Figure 9). Ireland reported that 
funding has now been made available for a DCR, meaning that the establishment of this service can now go 
ahead. There are, as yet, no DCRs introduced in the Centre and East sub-regions. More countries in Europe, and 
especially those with high numbers of PWID and high rates of HIV and other health harms, may find it useful to 
consider opening DCRs as part of a comprehensive response.  
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Figure 9. Geographical spread of DCRs in Europe 
 
Source: EMCDDA [13] 
Opioid Substitution Therapy (OST) 
Similarly, for OST, an intervention reported as having been implemented by 46 countries9, it is important to look in 
detail at the percentage of estimated opioid users receiving OST. Thirteen countries had no data on OST coverage. 
There is a very considerable range in coverage, from 83% in Norway to 0.6% in Kazakhstan. Only five countries 
(France, Luxembourg, Malta, Norway and Slovenia) reported that over 60% of opioid users were receiving OST. A 
further 10 countries reported percentages between 40 and 60% (Austria, Croatia, Denmark, Germany, Greece, 
Ireland, Netherlands, Portugal, Spain and the United Kingdom). It is noteworthy that all countries reporting over 
40% of opioid users receiving OST are EU/EEA countries. 
In contrast, nine countries reported that less than 5% of opioid users were receiving OST (Azerbaijan, Belarus, 
Kazakhstan, Kosovo, Kyrgyzstan, Moldova, Slovakia, Tajikistan and Ukraine). With the exception of Slovakia, all 
these countries are in the East region and are non-EU/EEA countries. Furthermore, many of these countries have 
high rates of HIV in this key population – with both Belarus and Ukraine having a prevalence rate of over 20% and 
Kyrgyzstan, Moldova and Tajikistan having prevalence rates between 11 and 20%. 
Figure 10. Available data on percentage of estimated opioid users receiving OST by country, 2018 
 
Source: EMCDDA Statistical Bulletin 2018 and ECDC Dublin Declaration monitoring 2018 
 
                                                                    
9 Slovakia, Russia and Uzbekistan do not implement OST in the community. Iceland, Liechtenstein, Monaco answered ‘Don’t 
know’ to this survey question. 
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Removing legal barriers to OST 
In Germany, the revision of the Narcotics Prescription Regulation in 2017 allows for more flexible and 
individualised OST and reduces legal barriers for physicians.  
Condom promotion and distribution programmes 
Countries were asked to report the percentage of PWID who used condoms the last time they had sex and the 
coverage of condom programmes among PWID. Condom use can prevent the transmission of HIV and other 
infections from PWID to their sexual partners. However, 26 countries (half of the responding countries) had no 
data on condom use at last sexual intercourse – further efforts are needed to collect these data in order to help 
support the sexual and reproductive health of PWID and their sexual partners. Of the 26 countries who could 
report data, values ranged from 63.5% in Montenegro to 15.1% in Azerbaijan. It is notable that only a small 
number of countries from the West sub-region were able to provide data for this indicator. 
In terms of condom programme coverage (Figure 11), 13% countries reported low coverage, 33% reported 
medium coverage, 13% reported high coverage and 6% reported full coverage of condom programmes among 
PWID. A total of 35% of countries reported either no coverage or ‘Don’t know/No data’.  
It is clear that there is a need to address the sexual health needs of PWID and, to this end, it is important to 
collect better data on the sexual behaviour and health needs of this key population. 
Figure 11. Percentage of PWID reporting using a condom the last time they had sexual intercourse across 
Europe and Central Asia (n=26) 
 
Figure 12. Estimated coverage of condom promotion and distribution programmes for PWID across Europe 
and Central Asia (n=52) 
 
Harm reduction in prisons 
A high percentage of people in prison inject drugs or have done so in the past. Prison offers an opportunity to 
provide harm reduction and healthcare services to PWID, some of whom may not previously have received such 
services. Conversely, in the absence of adequate drugs and health services for people who use drugs, the risk of 
unsafe drug use and the transmission of HIV and other blood-borne viruses (BBV) in prisons is high. In 2018, ECDC 
and EMCDDA published public health guidance entitled ‘Prevention and control of blood-borne viruses in prison 
settings’ [15], which sets out key principles for the provision of health services to prevent BBV transmission in 
prisons and the evidence base for effective interventions. These interventions include OST, NSPs, condoms and 
behavioural interventions, HBV vaccination, testing and treatment of HIV and viral hepatitis, and continuity of care. 
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In this report data on harm reduction in prisons draws on two sources. Data collected by EMCDDA are used for EU 
countries plus Norway and Turkey. For all other countries, data are drawn from the Dublin Declaration reporting 
process. 
Only five countries across the whole Region implement NSPs in prison (Germany, Kyrgyzstan, Luxembourg, Spain, 
and Switzerland) (Table 2). This is a far lower number than the 44 countries implementing NSPs in the community. 
In the ECDC/EMCDDA 2018 guidance there is reference to the principle of ‘equivalence of service provision’. The 
fact that a number of countries do operate NSPs in prison shows that it is possible and can bring health benefits. 
Other countries in the Region, and especially those with significant HIV epidemics among PWID, should examine 
the evidence for the value of NSPs in prison and consider implementation. 
Table 2. Needle and syringe programmes in prison settings 
NSPs in prisons Countries  
Implemented 
5 
 
West: Germany, Luxembourg, Spain, Switzerland 
East: Kyrgyzstan. 
Not implemented 
40 
 
West: Andorra, Austria, Belgium, Denmark, Finland, France, Greece, Iceland, Ireland, 
Israel, Italy, Malta, Netherlands, Norway, Portugal, Sweden, United Kingdom 
Centre: Albania, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, North Macedonia, 
Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey  
East: Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Latvia, Lithuania, 
Ukraine. 
Don’t know/no data 
7 
 
West: Liechtenstein, Monaco; 
Centre: Kosovo10; 
East: Moldova, Russia, Tajikistan, Uzbekistan. 
Source: EMCDDA Statistical Bulletin 2018 and ECDC Dublin Declaration monitoring 2018 
Respondents were asked about OST implementation in prison settings (Table 3). Among those countries that have 
a prevalence of HIV among PWID of 6% and above, the following do not implement OST in prison – Azerbaijan, 
Kazakhstan, Tajikistan, Belarus, Russia and Ukraine. Russia and Tajikistan do not provide OST in the community 
either.  
Table 3. Opioid substitution therapy in prison settings 
OST in prisons Countries  
Implemented 
32 
 
West: Andorra, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, 
Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland; 
United Kingdom; 
Centre: Albania, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, Kosovo11, North 
Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey;  
East: Armenia, Estonia, Georgia, Kyrgyzstan, Latvia, Lithuania, Moldova.  
Not implemented 
8 
 
West: Iceland, Israel;  
Centre: Slovakia; 
East: Azerbaijan, Belarus, Kazakhstan, Russia, Ukraine. 
Don’t know / No data 
12 
 
West: Liechtenstein, Monaco; 
Centre: Montenegro; 
East: Tajikistan, Uzbekistan. 
Source: EMCDDA Statistical Bulletin 2018 and ECDC Dublin Declaration monitoring 2018 
  
 
                                                                    
10 This designation is without prejudice to positions on status and is in line with UNSC 1244 and the ICJ Opinion on the Kosovo 
Declaration of Independence 
11 See footnote 12 above. 
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EMCDDA data indicate that for EMCDDA member countries in recent years, the gap between the availability of OST 
as a treatment approach for people who use opioids in the community and in prison is slowly closing (Figure 13). 
Among the 30 EMCDDA member countries (EU-28, plus Norway and Turkey) only Slovakia does not provide the 
treatment, either in prison settings or in the community. However, the coverage in prison is often low and 
treatment quality unclear. In four of the 29 countries (Cyprus, Latvia, Lithuania and the Netherlands), OST can only 
be continued in prison if treatment was started in the community. It is not possible in these four countries to 
initiate OST in prison. 
Figure 13. Opioid Substitution Treatment: cumulative number of EU countries introducing OST in community 
and prison settings 
Source: EMCDDA Statistical Bulletin 2018 
In terms of coverage, EMCDDA calculates as proxy for the coverage of prison OST the number of prisoners 
receiving OST per 100 prisoners, using the entire prisoner population as denominator (Figure 14). There are 
significant differences in this proportion between countries, ranging from more than 10% of all prisoners in Croatia, 
Italy, Luxembourg, Slovenia and the UK to below 1% in Bulgaria, Czech Republic, Latvia, Hungary, Poland, 
Romania and Sweden. There are significant challenges to turning policy into practice in prison settings.  
Figure 14. Proxy for OST coverage among prisoners in 2017: number of OST patients in prison per 100 
prisoners (on a given day) 
 
Source: EMCDDA Statistical Bulletin 2018 
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Preventing HIV transmission 
Testing guidelines and testing rates 
HIV testing is a key intervention to ensure people with HIV are diagnosed as early as possible to benefit from 
treatment and prevent both morbidity and mortality. It is also a key prevention intervention as diagnosis can 
support changes in risk behaviour and is the necessary first step in accessing treatment in order to achieve a 
suppressed viral load and become non-infectious. Of 40 countries with testing guidelines, 31 included content on 
specific key populations and 25 mentioned PWID. Twenty-eight countries had guidelines which made 
recommendations on how often key populations should be tested for HIV, with eight countries recommending that 
PWID should test every six months and 13 countries recommending annual testing, as per ECDC/EMCDDA 
guidance [12]. Further detail is provided in Annex 2. 
Thirty-three countries were able to provide data on PWID testing rates over a 12-month period (see Figure 15). 
Four countries (Bulgaria, Luxembourg, Sweden and the United Kingdom) reported that over 70% of PWID were 
tested in the previous 12 months. Ten further countries reported values between 50 and 70%; ten countries 
reported between 20 and 49%; nine countries reported less than 20%; and 22 countries did not report any data. 
Furthermore, data reported by three countries were from 2012, 2013 and 2014, respectively. Again, further efforts 
are needed to survey these populations in many countries to gain a better idea of unmet needs.  
Figure 15. Available data on HIV test uptake (tested in last 12 months) among PWID, 2012–2017 
 
Implementation of different HIV testing modes  
It is important to implement a range of HIV testing modes to maximise reach to all populations affected by HIV. 
Respondents were asked about the degree of coverage in their country for a range of different testing strategies. 
While the questionnaire did not specifically ask about testing in drug treatment services, there was low coverage 
reported for testing in ‘community’ and ‘other health settings’. Coverage of provider-initiated testing in primary and 
secondary care was reported to be higher. While these are settings where PWID might be more likely to be 
diagnosed, much more needs to be done to extend the reach of such testing interventions.  
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Figure 16. Level of implementation of different testing modes in Europe and Central Asia, reported in 201812 
 
Increasing HIV testing uptake among PWID 
In Germany, various approaches are being used to increase testing uptake among PWID. Community-based 
testing has been expanded and testing is also now being offered in low-threshold drug services. Barriers to 
testing are being removed, such as the need to return to testing sites to receive test results. This is particularly 
important as point-of-care testing is increasingly being used. Finally, a testing campaign focusing on drug users 
aims to normalise routine HIV and hepatitis testing.  
Late HIV diagnoses 
HIV testing is vitally important to ensure early diagnosis of people living with HIV so that they can maximise the 
benefits of HIV treatment. Late diagnosis (defined as diagnosis with a CD4 count of <350/mm3) increases short-
term mortality risk, decreases life expectancy and results in greater morbidity. In addition, the earlier people are 
diagnosed, the sooner they can both adopt safer sex behaviour and become non-infectious once they are receiving 
effective treatment. Someone diagnosed late will tend to have had HIV for at least three to four years prior to their 
diagnosis [16]. There is therefore also a significant wider public health benefit to effective HIV testing among 
people who inject drugs.  
Nevertheless, late diagnosis rates remain stubbornly high. For PWID the overall late diagnosis rate across the 
European Region in 2017 was 55%, with little variation across the three sub-regions [2]. This compares with a 
53% late diagnosis rate for all people newly diagnosed with HIV in 2017. Only for the key population of men who 
have sex with men (MSM) was the late diagnosis rate significantly lower (though still too high) at 39%.  
  
 
                                                                    
12 Countries were asked which testing modes were implemented and what level of coverage was implemented. Based on the 
WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is 
of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could 
choose from a scale of coverage, as follows: No coverage: the service is not provided. Low coverage: <30% of the population 
can use the effective, affordable service. Medium coverage: 30–60% of the population can use the effective, affordable service. 
High coverage: 61–95% of the population can use the effective, affordable service. Full coverage: 95–100% of the population can 
use the effective, affordable service. 
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Figure 17. Late diagnosis by exposure route, 2017 
 
Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2018 – 2017 data 
EMCDDA collect data on the percentage of PWID entering drug treatment who report never having been tested for 
HIV (see Figure 18). ‘Never tested’ rates range from 28% (Denmark) to 4% (Latvia and Bulgaria). There is no clear 
correlation between EMCDDA data and the Dublin Declaration responses on testing rates in the previous 12 
months. Of those countries reporting over 70% testing in the previous 12 months only Bulgaria also provided data 
to EMCDDA on ‘ever/never’ testing rates for those entering prison – 4% had never tested which confirms the 
relative effectiveness of Bulgaria’s testing interventions for PWID.  
Figure 18. Percentage of PWID entering drug treatment in 2017 who report having never having been 
tested for HIV 
Source: EMCDDA (2018). TDI monitoring system 
Treatment guidelines 
Ensuring prompt access to HIV treatment not only keeps the person living with HIV healthy, it also eliminates the 
risk of sexual transmission once the person has reached viral suppression. Since 2014, there has been a significant 
increase in the number of countries in Europe and Central Asia with guidance advising prompt treatment following 
diagnosis, regardless of CD4 count. A total of 46 countries have now adopted this advice, in accordance with WHO 
[17] and EACS [18] clinical guidelines on the use of ART for treating and preventing HIV infection. However, six 
countries continue to maintain a CD4 threshold for initiating HIV treatment – Azerbaijan, Bosnia & Herzegovina13, 
Latvia, Moldova, Tajikistan and Uzbekistan. Given the significant prevalence of HIV among PWID in some of these 
countries, implementation of the guidelines on treatment initiation regardless of CD4 count should be considered. 
  
 
                                                                    
13 Although Bosnia & Herzegovina did not officially submit data to the 2018 Dublin Declaration monitoring round, current 
treatment policy was confirmed via email by the country focal point. 
52%
59%
55%
55%
0% 10% 20% 30% 40% 50% 60% 70%
All new diagnoses
Hetero
IDU
MSM
Total WHO European Region East Centre West
0%
5%
10%
15%
20%
25%
30%
HIV and people who inject drugs TECHNICAL REPORT 
18 
Figure 19. Changing policy on initiation of ART by CD4 count 
 
Whilst the widespread implementation of treatment as prevention policies indicates positive progress, it is less clear 
whether these policies are being implemented in practice. As Figure 6b in the continuum of care section shows, 
disaggregated data on treatment coverage among PWID remain limited. Among the small number of countries that 
did report the percentage of PWID diagnosed who are on treatment, there are a number with low percentages on 
treatment even though they have a policy of treatment initiation regardless of CD4 count – Greece, Belgium, 
Kazakhstan, Bulgaria and Belarus. Furthermore, in Figure 6c we can see that in some countries the proportion 
people on treatment who are virally suppressed is surprisingly low – Azerbaijan, Kazakhstan, Bulgaria – which 
indicates the reality of treatment provision and access might be more problematic. 
Improving adherence to treatment and retention in care among 
PWID 
In Ireland, one HIV clinic in Dublin has a number of walk-in slots which facilitates 'open appointments' for 
patients where adherence to treatment and retention in care is a challenge. There is also a consultant-led 
homeless liaison service with a multi-disciplinary team approach (including keyworkers, outreach, nursing and 
hostel staff) working to improve retention. 
Improving health-related quality of life 
Vaccination programmes 
Vaccination programmes for PWID are vital in supporting good health and preventing onward transmission, 
including for those PWID living with HIV. However, data suggest there is much more to do to improve vaccination 
coverage for PWID. For hepatitis A and tetanus the percentage of countries that report either no coverage or ‘Don’t 
know/no data’ are 65% and 58%, respectively. The figure is not much better for hepatitis B at 48%. 
Figure 20. Estimated coverage of HBV, HAV and tetanus vaccination programmes for PWID across Europe 
and Central Asia (n=52) 
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Integration of other services into HIV care 
The Dublin Declaration questionnaire 2018 asked whether there are systems in place to ensure that PLHIV who are 
on treatment are linked to other care programmes and services that can improve their general quality of life when 
living with HIV. Figure 21 indicates that many of the health-related services that are particularly important to PWID 
living with HIV, such as drugs and alcohol support or hepatitis and TB services, are well integrated into HIV care in 
a majority of countries. However, services which could have a significant impact on the quality of life of PWID living 
with HIV, such as housing and legal support, are not well integrated. 
Figure 21. Linkage to other support services for people receiving HIV care 
 
Addressing barriers to services 
Data on barriers to prevention, testing and treatment in key populations were collected in previous rounds of 
Dublin Declaration reporting, most recently in 2016 [19]. Barriers have tended to remain constant over time and 
for PWID these include stigma and discrimination, gaps in prevention programmes (e.g. insufficient NSP coverage, 
insufficient attention to medical care/BBVs, lack of attention to specific sub-groups of PWID), legal barriers such as 
criminalisation/punitive legislation, and a failure to deliver treatment at scale [20].  
In 2018, 20 countries reported that they had taken action to address barriers to HIV prevention, testing and 
treatment services which had a direct impact on PWID. Sixteen countries had taken action to remove barriers to 
prevention services for PWID, eight countries had taken action on barriers to testing, and ten countries had taken 
action on barriers to treatment for PWID. 
Since criminalisation of drug use remains widespread across the European Region [21], it was promising to see a 
number of countries enacting changes to reduce legal barriers to support for people who inject drugs. Both Malta 
and Ireland reported actions taking a more public-health focused approach to drug policy, moving away from 
criminalisation, particularly for minor offences.  
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Moving towards a public health approach to people who inject 
drugs 
Malta is taking steps to move away from a penal approach to drug policy and towards a more public health 
focussed approach. In April 2015, the Drug Dependence (Treatment not Imprisonment) Act 2014 came into 
force. Under this Act, a person found in possession of a small amount of drugs for personal use will be tried in 
front of the Commissioner of Justice. If found guilty, a fine of EUR 50 to EUR 100 will be imposed for 
possession of cannabis or EUR 75 to EUR 125 for possession of other drugs. Any offender who commits a 
second offence within a period of two years will be required to attend the Drug Offenders Rehabilitation Board, 
where he or she will be assessed for drug dependence and any necessary order issued. Failure to comply with 
an order may be punishable by a fine or three months in prison. A person found in possession of one cannabis 
plant for personal use will not be liable to a mandatory prison term. In the case of an offender who commits a 
limited number of offences as a result of drug dependence, the Court may assume the function of a drug court 
and refer the offender to the Drug Offenders Rehabilitation Board. 
In addition, other actions taken included changes to laws and policies (four countries); increases in funding (four 
countries); improvements to service delivery (11 countries); improvements in surveillance and monitoring (three 
countries); increased integration with other health services or support services (four countries); interventions to 
improve adherence and retention (two countries); interventions to improve education and awareness among health 
professionals (four countries) and PWID (nine countries); and interventions to reduce stigma and discrimination 
(two countries). Some of these actions have been included as case studies throughout this report. 
With regard to new and emerging barriers to treatment for PWID, Ireland reported that increases in homelessness 
and unstable accommodation since the previous monitoring round have resulted in patients missing appointments 
and poor adherence to medication regimes.  
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Conclusions and priorities for action 
PWID continue to be a key population affected by HIV in the European Region. However, the extent of this HIV 
burden is notably imbalanced across the sub-regions, with the East sub-region, even in the absence of data from 
Russia, reporting in 2017 that 24.1% of its new HIV diagnoses were among PWID (compared with 2.7% in both 
other sub-regions).  
There is encouraging evidence of a decline in new HIV diagnoses among PWID in some countries, especially 
Ukraine and Azerbaijan, but also in Estonia, Portugal, Austria and Spain. However, this decline is not observed 
across the whole Region. It will be important to identify and share the reasons for this encouraging trend and 
implement shared learning. There is, of course, already a very strong evidence base for what works in reducing 
HIV transmission among this population. Most importantly, a comprehensive package of harm reduction measures 
needs to be implemented. The 2018 Dublin Declaration monitoring survey found that only eight countries have 
achieved the 2020 minimum target set by WHO’s Regional Office for Europe for availability of clean injecting 
equipment for PWID. It is hardly surprising, given such inadequate provision, that HIV and other BBVs continue to 
be transmitted. Similarly, we know that OST reduces heroin use and injecting, and supports people in moving into 
structured treatment and wide-ranging support for a variety of needs. Whilst 42 countries stated they had a policy 
of providing OST to PWID, most countries, if they had data at all, reported relatively low percentages of PWID on 
OST. Although it is necessary to have the right policies in place, this on its own is insufficient. Resources, services 
and monitoring need to be provided to ensure that as many PWID as possible can and do access such prevention 
measures. There is a proven synergistic effect of combining harm reduction at scale (NSPs and OST) with effective 
treatment of infections (e.g. ART for HIV). 
Whilst NSPs and OST are the most commonly cited elements to harm reduction, there are other important 
measures which should be combined with these to reduce harm, such as HIV transmission. The evidence suggests 
not enough is being done to support safer sex in this population, and there is more to do on wider healthcare 
including STI testing and treatment, and vaccination programmes. Far greater efforts need to be made to 
overcome the barriers to healthcare access experienced by PWID, and there should be monitoring of, and targets 
to reduce, rates of morbidity and mortality in this population. 
It is encouraging to see the gap in OST provision in prisons across Europe slowly closing, especially in EMCDDA 
member countries. However, policies do not always determine the level of provision of services, and the rates of 
prisoners receiving the treatment vary widely across the Region. Even if policies are now in place to provide OST to 
people during their time in prison, coverage needs to be significantly improved. 
Data collection in relation to HIV care for PWID remains poor across Europe, with only seven countries being able 
to report on all four stages of the continuum of care. There was relatively little progress in data collection on the 
continuum of care for PWID between 2016 and 2018. This report also makes it clear that insufficient surveillance 
and data collection is not confined to the stages of the continuum of care. For example, there are similar gaps and 
deficiencies across Europe in relation to coverage of harm reduction measures. There are countries in all three sub-
regions which need to improve data collection. Where the proportion of PWID among all people living with 
diagnosed HIV is relatively low there is an even greater risk that overall data for the population of people living 
with HIV can disguise, in the absence of disaggregated data, significant health inequalities experienced by PWID.  
Priority options for action 
Strengthen prevention programmes for PWID 
• All countries which have not yet reached the international standard of >200 clean syringes distributed per 
PWID per year should consider developing and implementing a plan to do so, to meet WHO targets. 
• Greater efforts need to be made to ensure that opioid users can easily access effective treatment, such as 
OST, especially in the East sub-region. All countries should be aiming in the short- to medium-term to meet 
WHO’s 40% target for the Region, and countries which have already met this target should consider 
adopting more ambitious targets. 
• Cities in the European Region that have not as yet introduced Drug Consumption Rooms (DCRs) should 
review the international evidence for their effectiveness, consider whether they can meet needs among 
PWID in their locality, and consider piloting/introducing DCRs when the evidence suggests they can help 
reduce HIV transmission and other harming behaviour on a local scale.  
• The quality, accessibility and acceptability of condom promotion and distribution programmes for PWID 
should be reviewed in order to increase condom uptake and usage. 
  
HIV and people who inject drugs TECHNICAL REPORT 
22 
• In accordance with ECDC/EMCDA guidance, comprehensive harm reduction interventions should be 
implemented in prisons to reduce health harms arising from injecting drug use and more support provided 
to people in accessing treatment and care, including OST. All countries should consider making OST 
available for PWID in prison, both for initiation and continuation of treatment. 
• All countries should consider reviewing barriers to PWID accessing HIV prevention, testing, treatment and 
care, and consider, in light of national and international recommended best practices, measures to remove 
those barriers. In addition to the measures identified above, they should consider interventions against 
stigma and discrimination, reviews of punitive laws affecting PWID, enhanced testing efforts (for example in 
drug treatment services and community settings), and improved treatment for the health needs of PWID, 
such as testing for other BBVs. 
• Infectious disease testing, treatment and care for PWID should ideally be integrated, along with vaccination 
programmes, into wider healthcare and health promotion.  
Improve surveillance, research and data collection 
• More and better data on PWID need to be collected, especially for all stages of the continuum of care – this 
should be considered as a priority for all countries in the European Region. 
• Other data that would be very useful to collect across Europe include new diagnoses and prevalence data 
for PWID, the percentage of PWID who have tested in the last 12 months, uptake of all key 
prevention/harm reduction interventions, prison-specific data, health outcomes for PWID, 
adherence/retention in treatment (especially in the East sub-region), and epidemiological data on 
transmission among sexual partners of PWID. 
• The views of PWID and service users on the availability, accessibility and quality of services could be 
regularly collected and published, and ideally the survey process should be co-produced with PWID to be 
acceptable to and trusted by them. 
• Assumptions on coverage and service delivery for PWID could be compared against other relevant data 
sources and civil society perspectives to improve accuracy. 
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Annex 1. Combination Prevention for PWID 
NSP – Needle and Syringe Programmes  CBT – Community-based HIV testing (medical provider) PISC - Provider-initiated HIV testing in secondary care 
NSPP – Needle and Syringe Programmes in Prisons SS – Self sampling TOS – HIV testing in other settings 
OST – Opioid Substitution Therapy ST – Self testing PN – Assisted partner notification 
OSTP - Opioid Substitution Therapy in Prisons LPT – Community-based HIV testing (lay provider) ICT – HIV indicator condition-guided testing  
DCR – Drug Consumption Rooms AT – Routine antenatal testing TASP – Treatment as Prevention 
C – Condom promotion and distribution programmes RSH – Routine HIV testing in sexual health clinics HAV – Hepatitis A vaccination programme 
BC – HIV-related health promotion or behaviour change programmes PIPC – Provider-initiated HIV testing in primary care HBV – Hepatitis B vaccination programme 
TV – Tetanus vaccination programme STITT – STI testing and treatment  
 
WHO 
Region Country NSP NSPP14 OST15 OSTP16 DCR17 C BC CBT SS ST LPT AT RSH PIPC PISC TOS PN ICT TASP HAV HBV TV STITT 
W
es
t 
Andorra                                               
Austria                                               
Belgium                                                 
Denmark                                                 
Finland                                                 
France                                                 
Germany                                                 
Greece                                                 
Iceland                                               
Ireland                                                 
Israel                                               
Italy                                                 
Liechtenstein                                               
Luxembourg                                                 
Malta                                                 
 
                                                                    
14 For EU countries plus Norway and Turkey, EMCDDA data were used to determine whether NSPs are available in prisons. 
15 EMCDDA report that OST is available in the community in Sweden and Turkey. No information is available on coverage. 
16 Response categories for whether OST is available in prisons only included the option of yes (categorised as green) or no (categorised as red). Data for EU countries plus Norway and Turkey are 
from EMCDDA and for other countries are from the Dublin Declaration reporting process. 
17 Response categories for whether DCRs are implemented only included the option of yes (categorised as green) or no (categorised as red). This data was provided by EMCDDA. 
 
Implemented with high to full coverage Implemented with low to medium coverage Not implemented Don’t know / No response 
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WHO 
Region Country NSP NSPP14 OST15 OSTP16 DCR17 C BC CBT SS ST LPT AT RSH PIPC PISC TOS PN ICT TASP HAV HBV TV STITT 
Monaco                                               
Netherlands                                                 
Norway                                                 
Portugal                                                 
Spain                                                 
Sweden                                                 
Switzerland                                                 
United 
Kingdom                                                 
Ce
nt
re
 
Albania                                               
Bulgaria                                                 
Croatia                                                 
Cyprus                                                 
Czech 
Republic                                                 
Hungary                                               
Kosovo                                               
North 
Macedonia                                               
Montenegro                                               
Poland                                                 
Romania                                               
Serbia                                               
Slovakia                                               
Slovenia                                                 
Turkey                                               
Ea
st
 
Armenia                                               
Azerbaijan                                               
Belarus                                               
Estonia                                                 
Georgia                                               
Kazakhstan                                               
Kyrgyzstan                                               
Latvia                                                 
Lithuania                                                 
Moldova                                               
Russia                                               
Tajikistan                                               
Ukraine                                               
Uzbekistan                                               
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Annex 2. Testing guidelines 
WHO 
sub-
region 
Country 
Are there any national policies 
or guidelines in your country 
that cover HIV testing 
interventions and strategies? 
Do the guidelines have content 
on specific key populations? Do they mention PWID? 
Do the guidelines make 
recommendations on how 
often key populations should 
be tested for HIV? 
Do they mention PWID? 
W
es
t 
Andorra No         
Austria Yes No   No   
Belgium   No         
Denmark   Yes Yes Yes Yes No 
Finland   Yes No   No   
France   Yes Yes Yes Yes Yes - once a year 
Greece   Yes Yes Yes Yes Yes - every 6 months 
Iceland No         
Ireland   No         
Israel Yes Yes Yes No   
Italy   Yes Yes Yes Yes Yes - every 6 months 
Liechtenstein           
Luxembourg   Yes Yes Yes Yes Yes - once a year 
Malta   Yes Yes Yes Yes Yes - every 6 months 
Monaco No response         
Netherlands   Yes Yes No Yes No 
Norway   Yes Yes   Yes No 
Portugal   Yes Yes Yes Yes Yes - once a year 
Spain   Yes Yes Yes Yes Yes - once a year 
Sweden   Yes Yes Yes No   
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WHO 
sub-
region 
Country 
Are there any national policies 
or guidelines in your country 
that cover HIV testing 
interventions and strategies? 
Do the guidelines have content 
on specific key populations? Do they mention PWID? 
Do the guidelines make 
recommendations on how 
often key populations should 
be tested for HIV? 
Do they mention PWID? 
Switzerland   Yes Yes Yes No   
United Kingdom   Yes Yes Yes Yes Yes - once a year 
Germany   Yes Yes Yes Yes Yes - once a year 
Ce
ntr
e 
Albania Yes No   No   
Bulgaria   Yes Yes No Yes Yes - once a year 
Croatia   Yes Yes Yes No   
Cyprus   No         
Czech Republic   Yes No   No   
Hungary Yes No   No   
Kosovo Yes Yes Yes Yes Yes - every 6 months 
North Macedonia Yes Yes Yes Yes Yes - every 6 months 
Montenegro No         
Romania Yes Yes Yes Yes Yes - once a year 
Serbia Yes Yes No No   
Slovakia No         
Slovenia   Yes Yes Yes Yes Yes - once a year 
Turkey Yes No   No   
Poland   Yes Yes No Yes No 
Ea
st 
Armenia Yes No   Yes No 
Azerbaijan Yes Yes Yes Yes Yes - once a year 
Belarus Yes Yes Yes Yes Yes - every 6 months 
Estonia   Yes Yes Yes Yes Yes - once a year 
TECHNICAL REPORT HIV and people who inject drugs 
28 
WHO 
sub-
region 
Country 
Are there any national policies 
or guidelines in your country 
that cover HIV testing 
interventions and strategies? 
Do the guidelines have content 
on specific key populations? Do they mention PWID? 
Do the guidelines make 
recommendations on how 
often key populations should 
be tested for HIV? 
Do they mention PWID? 
Georgia Yes No   No   
Kazakhstan Yes Yes Yes Yes Yes - once a year 
Kyrgyzstan Yes Yes Yes Yes Yes - every 6 months 
Latvia   No         
Lithuania   Yes Yes Yes Yes Yes - once a year 
Moldova Yes Yes Yes Yes Yes - every 6 months 
Russia No response         
Tajikistan Yes No   Yes No 
Ukraine Yes Yes No Yes No 
Uzbekistan No response         
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